COVID-19

 

The Rheumatology Network COVID-19 clinical focus page provides information on the latest COVID-19 news, study and clinical trial findings, and clinical guideline updates for the treatment of COVID-19. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for COVID-19 drugs.

Rheumatology Research Foundation Announces Additional Funds for Telehealth Studies

March 17, 2021

This week, Rheumatology Network sat down to interview S. Louis Bridges, MD, PhD, to highlight the availability of funds for projects exploring telehealth. Bridges is the President of the Rheumatology Research Foundation, as well as Physician-in-Chief and Chair of the Department of Medicine at the Hospital for Special Surgery (HSS), as well as Chief of the Division of Rheumatology at HSS and Weill Cornell College of Medicine.

Rheumatoid Arthritis Quiz: COVID-19 and RA Treatment

February 25, 2021

Some treatments for rheumatic diseases have shown promise for treating COVID-19, but many should be avoided in patients with confirmed or suspected COVID-19. How much do you know about the use of treatments for rheumatic diseases in patients with COVID-19? Take our quiz to find out.

American College of Rheumatology Releases COVID-19 Vaccine Clinical Guidance

February 18, 2021

The American College of Rheumatology (ACR) has published guidance regarding coronavirus disease 2019 (COVID-19) vaccination for patients with rheumatic diseases, with emphasis placed on prioritizing immunocompromised patients to receive the vaccine.

How COVID-19 Has Altered Assessment and Treatment of Osteoporosis

February 15, 2021

A study published in Osteoporosis International focused on the changes that have occurred over the course of the pandemic for patients with osteoporosis and found that there have been delays in dual-energy X-ray absorptiometry (DXA) scanning, problems with medication supply, a decrease in face-to-face consultations, and reductions in parenteral medication delivery.

Tocilizumab Does Not Improve Outcomes for Patients With Severe COVID-19

February 03, 2021

Tocilizumab is an interleukin 6 (an inflammatory cytokine) inhibitor approved for treating a variety of rheumatic diseases, including rheumatoid arthritis. As studies have shown that an increased level of interleukin 6 directly correlates to poor COVID-19 outcomes, investigators speculated that blocking this activity could be a helpful tool in treating the virus and lessening its severity.

Alice Fike, MS, NP: Latino Patients Disproportionately Affected by COVID-19

February 02, 2021

This week, we sat down for an interview with Alice Fike, MS, NP, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), to discuss her study titled “Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients.” The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by coronavirus disease 2019 (COVID-19).

Latino Patients With Rheumatic Diseases are at Higher Risk of Contracting COVID-19

February 01, 2021

The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by COVID-19. Of the patients observed, 32 (18%) developed COVID-19 during the study period, meaning incidence rates were 5- to 11-fold higher than the general population (1,540 to 3,431/100,000).